CDK6 amplification mediated resistance to abemaciclib in breast cancer cells (Yang et al., 2017), while elevated CDK6 protein levels were associated with acquired resistance to endocrine treatment (Correction, 2016). This evidence concerns the gene CDK6 and breast carcinoma.